Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 16/20 | 0.58 |
| ▸ | NOTCH3 | Q9UM47 | 13/20 | 0.58 |
| ▸ | RBPJ | Q06330 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15631538 | 1.00 | NOTCH1 (0.58) | NOTCH1NOTCH3RBPJMAPK14IKBKB | |
| SCHEMBL15608508 | 0.86 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL15608509 | 0.86 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL18174929 | 0.86 | NOTCH1 (0.48) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL9865175 | 0.83 | NOTCH1 (0.50) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL9865173 | 0.83 | NOTCH1 (0.50) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL9865168 | 0.83 | NOTCH1 (0.50) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL15622551 | 0.83 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL15629462 | 0.83 | NOTCH1 (0.54) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL15622343 | 0.82 | NOTCH1 (0.45) | NOTCH1NOTCH3RBPJ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897945-B1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2897945-B1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2897954-B1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2897947-B1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2897954-B1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9273014-B2 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9133139-B2 | Fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150218111-A1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-06 | — | — | US | disclosed |
| EP-2897954-A1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150166489-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-8999918-B2 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140087992-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-27 | — | — | US | disclosed |
| WO-2014047392-A1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047392-A1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140087992-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | CNR1, ROR1, RORB | NOTCH1 71/4885NOTCH3 47/4885RBPJ 136/4885 |
| US-20150218111-A1 | FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, CNKSR1 | NOTCH1 18/4885NOTCH3 46/4885RBPJ 230/4885 |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 61/4885NOTCH3 34/4885RBPJ 190/4885 |
| US-20150166489-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | CNR1, ROR1, RORB | NOTCH1 71/4885NOTCH3 47/4885RBPJ 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.